Skip to search formSkip to main contentSkip to account menu

ligelizumab

Known as: QGE031 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Antibodies, Anti-IdiotypicAntibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Ligelizumab for chronic spontaneous urticaria *
Chronic spontaneous urticaria (CSU) is a very disabling condition. It can be difficult to treat. Less than 50% of people respond… 
2020
2020
Long-term treatment with ligelizumab achieves prolonged symptom control during the post-treatment follow-up
2020
2020
Neue Medikamente gegen chronisch spontane Urtikaria
Vor allem für Patienten mit chronisch spontaner Urtikaria, bei denen Omalizumab nicht wirkt, werden zukünftig neue… 
2019
2019
P151 LIGELIZUMAB ACHIEVES SUSTAINED CONTROL OF ANGIOEDEMA IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA
2019
2019
P153 LIGELIZUMAB REDUCES RESCUE MEDICATION USE IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS
2019
2019
Bronchoprovocation studies to define mechanisms in asthma and airway inflammation
Bronchial provocations with a variety of stimuli have been widely used over the past 70 years in both asthma research as well as… 
2017
2017
IgE Depletion in Severe Asthma: What We Have and What Could Be Added in the Near Future
2015
2015
A PKPD mathematical model to determine efficacy of multiple doses of QGE031 (ligelizumab) vs. omalizumab and placebo in inhibiting skin responses in atopic asthmatics
Aim: QGE031, a humanised anti-IgE, was assessed in atopic subjects (sbts). PD endpoints were drug-IgE complexation, free IgE… 
2014
2014
Late-breaking abstract: Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting the allergen-induced early asthmatic response
Background The effect of QGE031, a high-affinity humanized anti-IgE antibody, was evaluated versus omalizumab (OMA) and placebo… 
2013
2013
QGE031 high affinity anti-IgE: Tolerability, safety, pharmacokinetics and pharmacodynamics in atopic subjects
QGE031, a human anti-IgE with higher affinity than omalizumab (OMA), was evaluated in atopic subjects (18-55 years) in single… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)